Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Precision doses first patient in study of in vivo gene editing program in DMD - BioTuesdays

Precision Biosciences (NASDAQ: DTIL) has announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating its in vivo gene editing program, PBGENE-DMD, for the treatment of Duchenne muscular dystrophy (DMD). According to Precision, the first patient was dosed at Arkansas Children’s Hospital. The study is currently enrolling ambulatory DMD patients between the ages of two and seven with mutations between…

Precision BioSciences Commences Dosing in Phase I/II FUNCTION-DMD Study

Precision BioSciences, Inc. announced the dosing of the first patient in August in the Phase I/II FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). [Precision BioSciences, Inc.] Press Release

Precision BioSciences has dosed the first individual with their novel gene editing approach for individuals with Duchenne mutations between exons 45 and 55

Precision BioSciences has shared that the first participant in the FUNCTION_DMD clinical trial has received their investigational gene editing treatment, PBGENE-DMD.  PBGENE-DMD delivers ARCUS nucleases via AAV9 to cut out exons 45-55 of the dystrophin gene, a therapeutic approach amenable to individuals with Duchenne with mutations in that region. Link to press release: https://investor.precisionbiosciences.com/news-releases/news-release-detail…

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD is Precision's wholly ow…